[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595986":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":27,"centralContacts":35,"locations":41,"responsibleParty":71,"collaborators":11,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":11,"eligibilityCriteria":79,"healthyVolunteers":75,"sex":80,"minAge":81,"maxAge":11,"enrollmentInfo":82,"targetDuration":11,"studyType":85,"phases":86,"briefSummary":88,"conditions":89,"keywords":11,"overallStatus":43,"whyStopped":11,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"Keymed Biosciences Co.Ltd","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Low dose group(CM336)","EXPERIMENTAL",null,[13],"Biological: CM336 Injection(Low dose group)",{"label":15,"type":10,"description":11,"interventionNames":16},"High dose group(CM336)",[17],"Biological: CM336 Injection(High dose group)",[19,24],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":11},"BIOLOGICAL","CM336 Injection(Low dose group)","subcutaneous CM336 administration, step-up dosing, Dose and frequency of CM336 according to the protocol.",[9],{"type":20,"name":25,"description":22,"armGroupLabels":26,"otherNames":11},"CM336 Injection(High dose group)",[15],[28,32],{"name":29,"affiliation":30,"role":31},"Jian Li","Peking Union Medical College Hospital","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":31},"Gang An","Institute of Hematology & Blood Diseases Hospital, China",[36],{"name":37,"role":38,"phone":39,"phoneExt":11,"email":40},"Qian Jia","CONTACT","028-88610620","qianjia@keymedbio.com",[42,58],{"facility":30,"status":43,"city":44,"state":45,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Beijing","Beijing Municipality","China","CN",{"type":49,"coordinates":50},"Point",[51,52],116.39723,39.9075,{"lat":52,"lon":51},[55],{"name":29,"role":38,"phone":56,"phoneExt":11,"email":57},"86+18610852525","lijian@pumch.cn",{"facility":59,"status":43,"city":60,"state":61,"zip":11,"country":46,"countryCode":47,"cosmosGeoPoint":62,"geoPoint":66,"contacts":67},"Institute of Hematology & Blood Diseases Hospital","Tianjin","Tianjin Municipality",{"type":49,"coordinates":63},[64,65],117.17667,39.14222,{"lat":65,"lon":64},[68],{"name":33,"role":38,"phone":69,"phoneExt":11,"email":70},"86+13502181109","angang@ihcams.ac.cn",{"type":72,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100595986","phase-2-study-evaluating-the-efficacy-and-safety-of-cm336-injection-in-the-treatment-of-light-chain-amyloidosis-100595986",false,"NCT07039578","Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis","An Open-Label, Multi-Center, Phase II Clinical Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Relapsed or Refractory Primary Light-Chain Amyloidosis","Inclusion Criteria:\n\n* Voluntary provision of written informed consent and ability to comply with protocol requirements.\n* Age ≥18 years, any gender.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.\n* Confirmed diagnosis of primary light-chain (AL) amyloidosis.\n* Relapsed or refractory primary AL amyloidosis.\n* Measurable hematologic disease at screening (per protocol-defined criteria).\n* Involvement of ≥1 amyloid-affected organ.\n* Adequate organ function meeting all protocol-specified criteria within 3 days prior to first dose.\n\nExclusion Criteria:\n\n* Current or prior diagnosis of multiple myeloma.\n* Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose.\n* Clinically significant cardiovascular or cerebrovascular disease.\n* Any active or uncontrolled infection meeting protocol-defined criteria.\n* Any other condition deemed by the Investigator to preclude safe study participation.","ALL","18 Years",{"count":83,"type":84},90,"ESTIMATED","INTERVENTIONAL",[87],"PHASE2","to Evaluate the Efficacy and Safety of CM336 (BCMA\u002FCD3 Bispecific Antibody) in Adults with Relapsed or Refractory Primary Light-Chain Amyloidosis",[90],"Primary Light-Chain Amyloidosis","2025-11-20",{"date":93,"type":94},"2025-11-26","ACTUAL",{"date":96,"type":94},"2025-07-25",{"date":98,"type":84},"2029-07-31",{"name":5,"class":6},2]